Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.

Tilton JC, Amrine-Madsen H, Miamidian JL, Kitrinos KM, Pfaff J, Demarest JF, Ray N, Jeffrey JL, Labranche CC, Doms RW.

AIDS Res Hum Retroviruses. 2010 Jan;26(1):13-24. doi: 10.1089/aid.2009.0132.

2.

Virally induced CD4+ T cell depletion is not sufficient to induce AIDS in a natural host.

Milush JM, Reeves JD, Gordon SN, Zhou D, Muthukumar A, Kosub DA, Chacko E, Giavedoni LD, Ibegbu CC, Cole KS, Miamidian JL, Paiardini M, Barry AP, Staprans SI, Silvestri G, Sodora DL.

J Immunol. 2007 Sep 1;179(5):3047-56.

3.

Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching.

Pastore C, Nedellec R, Ramos A, Hartley O, Miamidian JL, Reeves JD, Mosier DE.

J Virol. 2007 Aug;81(15):8165-79. Epub 2007 May 16.

4.

Functional impact of HIV coreceptor-binding site mutations.

Biscone MJ, Miamidian JL, Muchiri JM, Baik SS, Lee FH, Doms RW, Reeves JD.

Virology. 2006 Jul 20;351(1):226-36. Epub 2006 Apr 21.

5.
6.

Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.

Reeves JD, Miamidian JL, Biscone MJ, Lee FH, Ahmad N, Pierson TC, Doms RW.

J Virol. 2004 May;78(10):5476-85.

7.

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.

Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, Pohlmann S, Sfakianos JN, Derdeyn CA, Blumenthal R, Hunter E, Doms RW.

Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54. Epub 2002 Nov 20.

Supplemental Content

Loading ...
Support Center